Non-clinical toxicology evaluation of BIA 10-2474

References

• Akassoglou K, Malester B, Xu J, Tessarollo L, Rosenbluth J, Chao MV. 2004. Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. Proc Natl Acad Sci U S A. 101:5075–5080.
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Loureiro A, Aires C, Fernandes-Lopes C, Sousa F, Palma N, Moser P, Soares-da-Silva P. 2018. Pharmacodynamic and ADME evaluation of FAAH inhibitor BIA 10-2474. Mol Biol Cell. 28:630. Abstract P2651.
   Google Scholar
• Bonifacio MJ, Moser P, Soares-da-Silva P. 2018. In-vivo selectivity profiling of BIA 10-2474 against serine hydrolases in the rat brain. Mol Biol Cell. 28:629. Abstract P2650.
   Google Scholar
• Bonifacio MJ, Sousa F, Aires C, Loureiro AI, Fernandes-Lopes C, Pires NM, Palma PN, Moser P, Soares-da-Silva P. 2020. Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474. Br J Pharmacol. 177:2123–2142.
   PubMed Web of Science ®Google Scholar
• Borrelli F, Izzo AA. 2009. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab. 23:33–49.
   PubMed Web of Science ®Google Scholar
• Chapman J, Azevedo AM. 2019. Splenomegaly. StatPearls. [updated 2019 May 6].
   Google Scholar
• De Vry J, Jentzsch KR, Kuhl E, Eckel G. 2004. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol. 15:1–12.
   PubMed Web of Science ®Google Scholar
• FDA. 2005. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.
   Google Scholar
• Gama H, Vieira M, Graça J, Chassard D, Massano J, Patat A, Santos A, Rocha F, Soares-da-Silva P. 2016. Preliminary safety evaluation in study BIA-10-2474-101. Proc British Pharmacol Soc. 16(1):188. http://wwwpa2onlineorg/abstract/abstractjsp?abid=33277&kw=2474&author=Rocha&cat=-1&period=-1
   Google Scholar
• Hardisty JF, Harris SB, Hayes WA, Weber K. 2020. Oral repeated-dose toxicity studies of BIA 10-2474 in beagle dogs. Regul Toxicol Pharmacol. 111:104555.
   PubMed Web of Science ®Google Scholar
• Harris SB, Hardisty JF, Hayes AW, Weber K. 2020. Developmental and reproductive toxicity studies of BIA 10-2474. Regul Toxicol Pharmacol. 111:104543.
   PubMed Web of Science ®Google Scholar
• Hasenoehrl C, Taschler U, Storr M, Schicho R. 2016. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil. 28:1765–1780.
   PubMed Web of Science ®Google Scholar
• Hayes AW. 2020. Commentary on BIA 10-2474. Regul Toxicol Pharmacol. 111:104541.
   PubMed Web of Science ®Google Scholar
• Hayes AW, Hardisty JF, Harris SB, Okazaki Y, Weber K. 2020. Oral repeated-dose toxicity studies of BIA 10-2474 in Wistar rat. Regul Toxicol Pharmacol. 111:104540.
   PubMed Web of Science ®Google Scholar
• Hayes AW, Hardisty JF, Harris SB, Weber K. 2020. The absence of genotoxicity of a novel fatty acid amide hydrolase inhibitor, BIA 10-2474. Regul Toxicol Pharmacol. 111:104556.
   PubMed Web of Science ®Google Scholar
• Hayes AW, Pressman P, Hardisty JF, Harris SB, Weber K. 2020. Oral repeated-dose toxicity studies of BIA 10-2474 in CD-1 mice. Regul Toxicol Pharmacol. 111:104557.
   PubMed Web of Science ®Google Scholar
• Hayes AW, Pressman P, Moser P, Soares-da-Silva P. 2020. Regulatory safety pharmacology evaluation of BIA 10-2474. J Pharmacol Toxicol Methods. 102:106677.
   PubMed Web of Science ®Google Scholar
• Huang Z, Ogasawara D, Seneviratne UI, Cognetta AB 3rd, Am Ende CW, Nason DM, Lapham K, Litchfield J, Johnson DS, Cravatt BF. 2019. Global portrait of protein targets of metabolites of the neurotoxic compound BIA 10-2474. ACS Chem Biol. 14:192–197.
   PubMed Web of Science ®Google Scholar
• Kerbrat A, Ferre JC, Fillatre P, Ronziere T, Vannier S, Carsin-Nicol B, Lavoue S, Verin M, Gauvrit JY, Le Tulzo Y, et al. 2016. Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. N Engl J Med. 375:1717–1725.
   PubMed Web of Science ®Google Scholar
• Kortz GD, Meier WA, Higgins RJ, French RA, McKiernan BC, Fatzer R, Zachary JF. 1997. Neuronal vacuolation and spinocerebellar degeneration in young Rottweiler dogs. Vet Pathol. 34:296–302.
   PubMed Web of Science ®Google Scholar
• Lee Y, Jo J, Chung HY, Pothoulakis C, Im E. 2016. Endocannabinoids in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 311:G655–G666.
   PubMed Web of Science ®Google Scholar
• Li GL, Winter H, Arends R, Jay GW, Le V, Young T, Huggins JP. 2012. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol. 73:706–716.
   PubMed Web of Science ®Google Scholar
• Loureiro AI, Lopes C, Bonifacio MJ, Moser P, Soares-da-Silva P. 2017. Pharmacokinetics and pharmacodynamics of BIA 10-2474, a novel FAAH inhibitor, following oral administration in the cynomolgus monkey. Proc British Pharmacol Soc. 16(1):212. http://wwwpa2onlineorg/abstract/abstractjsp?abid=33301&author=soares-da-silva&cat=-1&period=64
   Google Scholar
• CSST. 2016. Report by the Temporary Specialist Scientific Committee (TSSC): FAAH (Fatty Acid Amide Hydrolase), on the causes of the accident during a Phase 1 clinical trial in Rennes in January 2016. In: Santé ANdSdMedPd, editor. France: Saint-Denis.
   Google Scholar
• Pawsey S, Wood M, Browne H, Donaldson K, Christie M, Warrington S. 2016. Safety, tolerability and pharmacokinetics of FAAH inhibitor V158866: a double-blind, randomised, placebo-controlled phase I study in healthy volunteers. Drugs R D. 16:181–191.
   PubMed Web of Science ®Google Scholar
• Postnov A, Schmidt ME, Pemberton DJ, de Hoon J, van Hecken A, van den Boer M, Zannikos P, van der Ark P, Palmer JA, Rassnick S, et al. 2018. Fatty acid amide hydrolase inhibition by JNJ-42165279: a multiple-ascending dose and a positron emission tomography study in healthy volunteers. Clin Transl Sci. 11:397–404.
   PubMed Web of Science ®Google Scholar
• Rocha F, Santos A, Chassard D, Patat A, Astruc A, Falcão A, Gama H, Soares-da-Silva P. 2016. Tolerability, pharmacokinetic and pharmacodynamic profile of BIA 10-2474 in healthy volunteers following multiple ascending doses. Proc British Pharmacol Soc. 16(1):178. http://wwwpa2onlineorg/abstract/abstractjsp?abid=33267&kw=2474&author=Rocha&cat=-1&period=-1
   Google Scholar
• Rogers-Cotrone T, Burgess MP, Hancock SH, Hinckley J, Lowe K, Ehrich MF, Jortner BS. 2010. Vacuolation of sensory ganglion neuron cytoplasm in rats with long-term exposure to organophosphates. Toxicol Pathol. 38:554–559.
   PubMed Web of Science ®Google Scholar
• Toczek M, Malinowska B. 2018. Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci. 204:20–45.
   PubMed Web of Science ®Google Scholar
• van Esbroeck ACM, Janssen APA, Cognetta AB 3rd, Ogasawara D, Shpak G, van der Kroeg M, Kantae V, Baggelaar MP, de Vrij FMS, Deng H, et al. 2017. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 356:1084–1087.
   PubMed Web of Science ®Google Scholar
• Weber K, Hacker R, Hardisty JF, Harris SB, Hayes AW. 2020. Oral repeated-dose toxicity studies of BIA 10-2474 in cynomolgus monkeys. Regul Toxicol Pharmacol. 111:104547.
   PubMed Web of Science ®Google Scholar